Get started
Author

Ana Godoy-Ortíz

Observed names: A Ortiz, A. Godoy Ortiz, A. Godoy-Ortiz, Ana Godoy, Ana Godoy Ortiz, Ana Godoy-Ortiz, Godoy-Ortiz Ana
Observed institutions: Instituto de Salud Carlos III, Hospital Regional Universitario de Málaga, Centro de Investigación Biomédica en Red, Hospital Materno-Infantil, Andalusian Centre for Nanomedicine and Biotechnology, Roche (Spain), Spanish Ovarian Cancer Research Group, Hospital Clínico Universitario Virgen de la Victoria, Centro de Investigación Biomédica en Red de Cáncer, GEICAM – Spanish Breast Cancer Group, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga
ORCID: 0000-0002-5503-6946
Observed ORCID: 0000-0002-5503-6946
OpenAlex ID: A5026247805
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
2023 · Ana Oaknin, Laurence Gladieff, et al. · The Lancet · 267
PDF
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
2019 · Ana Godoy-Ortiz, Alfonso Sanchez-Muñoz, et al. · Frontiers in Oncology · 113
Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study
2021 · Sofía Ruiz-Medina, Silvia Gil, et al. · Cancers · 40
Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients
2017 · A. Godoy-Ortiz, Y. Plata, et al. · Clinical & Translational Oncology · 34
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
2020 · María Rosario Chica-Parrado, Ana Godoy-Ortiz, et al. · Cancers · 32
PDF
Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patients
2023 · Victoria Sánchez-Martín, Esperanza López-López, et al. · Clinica Chimica Acta · 30
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients
2024 · Alfonso Alba-Bernal, Ana Godoy-Ortiz, et al. · npj Breast Cancer · 29
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients
2020 · Nuria Ribelles, Jose M. Jerez, et al. · European Journal of Cancer · 26
Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management
2022 · Ana Godoy-Ortiz, Alfonso Alba-Bernal, et al. · Cancers · 22
Exercise in cancer patients: assistance levels and referral pathways—a position statement from the Spanish Society of Medical Oncology
2024 · Blanca Herrero López, Ana Cardeña-Gutiérrez, et al. · Clinical & Translational Oncology · 20
Abstract LBO1-02: Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial
2024 · Luca Gianni, Elisabetta Munzone, et al. · Cancer Research · 16
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
2023 · A. Oaknin, L. Gladieff, et al. · Annals of Oncology · 12
PDF
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis
2022 · Begoña Jiménez-Rodríguez, Alfonso Alba-Bernal, et al. · International Journal of Molecular Sciences · 11
PDF
Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
2017 · Manuel Cobo, Vanesa Gutierrez, et al. · Lung Cancer Targets and Therapy · 11
10O Efficacy according to PD-L1 status in the BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC)
2025 · U. De Giorgi, L. Mansi, et al. · ESMO Open · 5
PDF
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial
2024 · Jimmy Belotte, Brunella Felicetti, et al. · Trials · 5
Afatinib en pacientes con carcinoma escamoso de pulmón: contexto actual y opción de un tratamiento oral
2016 · Manuel Cobo, Vanesa Gutiérrez, et al. · Medicina Clínica · 5
427 BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent or recurrent cervical cancer
2024 · Ana Oaknin, Laurence Gladieff, et al. · International Journal of Gynecological Cancer · 3
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain
2026 · Alejandro Falcón-González, Elisenda Llabrés-Valenti, et al. · Frontiers in Oncology · 2
PDF
Abstract PO3-05-07: SOLTI-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
2024 · Eva Ciruelos, Cristina Saura, et al. · Cancer Research · 2
Abstract PS1-12-17: Frequency and Prognostic Significance of ESR1 Mutations Post-CDK4/6 inhibitors in ER+/HER2− Metastatic Breast Cancer: Real-World Data from the GEICAM_RegistEM Study
2026 · Á. Guerrero-Zotano, S. Antolín, et al. · Clinical Cancer Research · 1
BEATcc (ENGOT-CX10/GEICO 68-C/JGOG-1084/GOG-3030): A randomized phase III trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent, or recurrent cervical cancer
2024 · Ana Oaknin, Laurence Gladieff, et al. · Gynecologic Oncology · 1
722P Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
2024 · L. Gladieff, J. Martinez-Garcia, et al. · Annals of Oncology · 1
PDF
Highly Sensitive Detection of ctDNA in Early Breast Cancer using Plasma-SeqSensei™ and Droplet Digital PCR with Increased Blood Volumes
2023 · Victoria Sanchez-Martin, M. Roldán-Díaz, et al. · The Journal of Liquid Biopsy · 1
Predicting the risk of VISIT emergency department (ED) in lung cancer patients using machine learning.
2020 · Pablo Rodriguez-Brazzarola, Nuria Ribelles, et al. · Journal of Clinical Oncology · 1
Works count: 49
Citation count: 692
H-index: 12
I10-index: 14
Year
Topic
Type